BioGend Therapeutics Co., Ltd. (TPEX:6733)
Taiwan
· Delayed Price · Currency is TWD 28.90
-0.10 (-0.34%)
Apr 29, 2026, 9:29 AM CST
BioGend Therapeutics Company Description
BioGend Therapeutics Co., Ltd. engages in the research and development, and sale of orthopedic medical devices and related products.
The company offers RevoCart, an autologous cartilage repair system; and SoufCut, an autologous adipose tissue collection system.
It develops BiG-001, an osteoinductive bone graft substitute; BiG-006 for lumbar interbody fusion; and BiG-009, an autologous cartilage repair system for articaular cartilage.
The company operates in Taiwan, Hongkong, Chinese Mainland, and Malaysia. BioGend Therapeutics Co., Ltd. was founded in 2016 and is based in Taipei, Taiwan.
BioGend Therapeutics Co., Ltd.
| Country | Taiwan |
| Founded | 2016 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 27 |
| CEO | Te-Li Chen |
Contact Details
Address: No.3-2, Park Street Taipei, 115 Taiwan | |
| Phone | 886 2 2655 8366 |
| Website | biogend.com |
Stock Details
| Ticker Symbol | 6733 |
| Exchange | Taipei Exchange |
| Fiscal Year | January - December |
| Reporting Currency | TWD |
| ISIN Number | TW0006733009 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Te-Li Chen M.D., Ph.D. | Chairman and GM |
| Guifen Zhang | Senior Manager |
| Shuwei Zhao | Senior Manager |
| Bozhi Zhang | Senior Manager |
| Bowei Li | Senior Manager |